Key result
Thymoquinone attenuates acute cisplatin-induced cardiac injury in rats by reducing myocardial oxidative stress.
Why the study?
Cisplatin-induced cardiotoxicity is an underrecognized adverse effect limiting clinical use, with oxidative stress playing a central role.
Does thymoquinone prevent acute cisplatin-induced cardiotoxicity in a rat model?
Does thymoquinone prevent acute cisplatin-induced cardiotoxicity in a rat model?
Answers are grounded in this paper and cite their sources.
Thymoquinone provides biochemical and histopathological protection against acute cisplatin-induced cardiotoxicity in rats, though it does not significantly reverse electrophysiological abnormalities.
Cisplatin (CIS)-induced cardiotoxicity is an important but underrecognized adverse effect that may limit the clinical use of this widely employed chemotherapeutic agent. Oxidative stress (OS) plays a central role in CIS-related cardiac injury. This study aimed to investigate the potential protective effects of thymoquinone (TQ) against acute CIS-induced cardiotoxicity in rats. Thirty-two male Wistar albino rats were simple randomly divided into four groups: Control, CIS, TQ, and CIS + TQ. Acute cardiotoxicity was induced using a single i.p. dose of CIS (7 mg/kg), while TQ was administered i.p. at 5 mg/kg/day for 3 days; therefore, this protocol did not model chronic or cumulative CIS exposure. Hemodynamic parameters and electrocardiographic recordings were obtained to assess cardiac conduction and rhythm. Serum creatine kinase, troponin, and lactate dehydrogenase levels were measured as markers of myocardial injury. OS parameters in heart tissue were evaluated, and histopathological examination was performed. CIS administration induced significant cardiac injury, evidenced by increased arrhythmia incidence, alterations in QRS duration, elevated serum cardiac biomarkers, enhanced myocardial lipid peroxidation, depletion of antioxidant defenses, and marked histopathological damage. TQ co-administration significantly reduced serum cardiac injury markers, restored myocardial antioxidant status, and ameliorated histopathological alterations, while effects on electrophysiological abnormalities showed only a non-significant descriptive trend. TQ alone did not produce adverse cardiac effects. TQ attenuated biochemical, OS, and histopathological indicators of acute CIS-induced cardiac injury in rats. However, these preclinical findings do not establish therapeutic efficacy, and studies using chronic CIS treatment protocols, tumor-bearing animals, and clinical investigations are required before the potential adjunctive use of TQ can be considered.
No takes yet. Share an insight, caveat, or question.
Özhan et al. (2026) studied Cisplatin-induced cardiotoxicity (n=32). Thymoquinone vs. Cisplatin alone was evaluated on Myocardial oxidative stress parameters, particularly malondialdehyde (MDA) levels (p=<0.05). Thymoquinone co-administration significantly attenuated acute cisplatin-induced cardiac injury in rats by reducing myocardial oxidative stress and restoring antioxidant defenses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: